Boosting the go-to-market strategy and accelerating new product development for a pharma services leader

We partnered with CSafe to help the company serve the global pharma market safely deliver critical therapies to patients around the world by enhancing their go to market capabilities and creating new product offerings.

The Opportunity

CSafe provides cold chain packaging and logistics services designed to maintain high-value, temperature-sensitive biopharmaceutical cargo—a powerful technology built for the cold chain supply chain. With continued scientific advances, there is an increased demand for climate-controlled solutions for pharmaceutical transport. The company was well-positioned to service the global supply chain needs of the growing biopharmaceutical market.

The challenge

At the time of acquisition, CSafe had a high-quality product but had not yet penetrated most of the Global Top 20 pharma companies. The company primarily served the North American market, but had low awareness in EMEA and APAC regions.

The Results

We worked with CSafe to focus on Global Top 20 pharma companies—a key market opportunity. By leveraging our vast network of pharma relationships and collaborating with the management team to build a robust go-to-market strategy, install rigorous measurement capabilities and develop in-depth product and sales trainings, our partnership produced strong results.

Twofold capacity increase

The company more than doubled both its production and sales capacities to improve global coverage in key markets. It now serves almost all major pharmaceutical companies in the world.

Global impact

In recent years, CSafe was able to distribute more than 6 billion doses of the COVID-19 vaccine worldwide.

Related content

2023 Healthcare Trends and Our Outlook for 2024
Insights
2023 Healthcare Trends and Our Outlook for 2024 

Operational Challenges, Patent Cliffs & Biotech Funding Slowdown, and Generative AI Define 2023; Encouraging Prospects Emerge for 2024 Key Takeaways: The healthcare industry experienced a significant transformation in 2023, driven by three defining trends: operational challenges due to staffing shortages and evolving payment models, looming patent cliffs for pharma manufacturers and a biotech funding slowdown that impacted

Healthcare (HC)

For a list of all portfolio company investments made by THL since its inception, please click here.

Want to know more?

Learn more about our integrated approach to private equity

How we invest